Eli Lilly and Novo Nordisk Bet on Amylin to Power Next Wave of Obesity Treatments
Pharmaceutical leaders Eli Lilly and Novo Nordisk are developing amylin-targeting therapies to complement existing GLP-1 medications, offering alternatives for patients who plateau or cannot tolerate current treatments.
